Finally, we demonstrate that primary RCC tumors can be classified based on their relative activation of the MEK and mTOR pathways and that these different MEK/mTOR subtypes are associated with differences in overall survival. The gene discussed is MAP2K7; the disease is renal cell carcinoma.